A Phase II, Proof of Concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Protective Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in Healthy, HIV-infected Adults.
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2015
At a glance
- Drugs MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Aeras
- 10 Jun 2017 Biomarkers information updated
- 29 Oct 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 16 Jul 2013 Planned End Date changed from 1 Feb 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.